<DOC>
	<DOCNO>NCT02783820</DOCNO>
	<brief_summary>This Phase I study evaluate safety , tolerability pharmacokinetic property escalate single dos reformulate MMV390048 administer healthy men woman non-childbearing potential ( WNCBP ) fast condition ( Part A ) .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetic Profile Ascending Oral Doses MMV390048 , Part A</brief_title>
	<detailed_description>This Phase I study evaluate safety , tolerability pharmacokinetic property escalate single dos reformulate MMV390048 administer healthy men woman non-childbearing potential ( WNCBP ) fast condition ( Part A ) . Primary objective : • To evaluate safety tolerability single ascending dos MMV390048 administer orally healthy subject ( men WNCBP ) fast condition Secondary objective : • To describe pharmacokinetics MMV390048 healthy subject ( men WNCBP ) single oral dose administration</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<criteria>1 . Completion write informed consent process . 2 . Men WNCBP age 18 55 year , good health determine past medical history , physical examination , vital sign , electrocardiogram , laboratory test screen . 3 . Male subject agree use acceptable method contraception male subject 's partner could become pregnant time first administration study medication 130 ( 90+40 ) day follow administration investigational medicinal product . One follow acceptable method contraception must utilize : Condom occlusive cap ( diaphragm cervical/vault cap ) Surgical sterilization ( vasectomy documentation azoospermia ) barrier method ( condom occlusive cap [ diaphragm cervical/vault cap ] . The subject 's female partner use oral contraceptive ( combination estrogen/progesterone pills ) , injectable progesterone subdermal implant barrier method ( condom occlusive cap [ diaphragm cervical/vault cap ] . The subject 's female partner use medically prescribe topicallyapplied transdermal contraceptive patch barrier method ( condom occlusive cap [ diaphragm cervical/vault cap ] . The subject 's female partner undergone document tubal ligation ( female sterilization ) . In addition , barrier method ( condom occlusive cap [ diaphragm cervical/vault cap ] . The subject 's female partner undergone document placement intrauterine device intrauterine system . In addition , barrier method ( condom occlusive cap [ diaphragm cervical/vault cap ] . True abstinence : line prefer usual lifestyle subject . Periodic abstinence ( e.g . calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . Abstinent subject agree use 1 abovementioned contraceptive method , start sexual relationship study 100 day last dose study drug . 4 . Women subject must nonchildbearing potential ( WNCBP ) per one follow definition : Natural ( spontaneous ) postmenopausal define amenorrhoeic least 12 month without alternative medical cause screen follicle stimulate hormone level consistent local laboratory level postmenopause . Premenopausal irreversible surgical sterilization hysterectomy and/or bilateral oophorectomy salpingectomy least 6 month screen ( determine subject medical history ) . 5 . Haematology , clinical chemistry urinalysis result screen within local laboratory reference range , outside range , clinically significant judged Investigator . More specifically , serum creatinine , hepatic transaminase enzyme ( AST ALT ) , total bilirubin ( unless subject document Gilbert syndrome ) exceed upper laboratory norm haemoglobin must equal high low limit normal range . 6 . Total body weight great 50 kg body mass index ( BMI ) within range 18 32 kg/m2 ( inclusive ) . 7 . Nonsmoker exsmoker 90 day prior screen , smoke 5 cigarette per day determine history . Must able abstain smoking inpatient stay . 8 . Willing able comply schedule visit , treatment plan , laboratory test , study procedure . 9 . Agree stay contact study site duration study 2 week follow end study visit , provide update contact information necessary , current plan move away study area duration study . 1 . Male subject female partner ( ) ( ) pregnant lactate time administration study medication . 2 . Women childbearing potential , defined woman physiologically capable become pregnant , include woman whose career , lifestyle , sexual orientation precludes intercourse male partner woman whose partner sterilize vasectomy mean . 3 . Evidence history clinically significant haematological , renal , endocrine , pulmonary , gastrointestinal ( include gallbladder ) , cardiovascular ( include family history long QT syndrome sudden death ) , hepatic , psychiatric , neurologic , allergic disease ( include drug food allergy , anaphylaxis severe allergic reaction exclude untreated , asymptomatic , seasonal allergy time dose ) . 4 . History malignancy organ system ( localise basal cell carcinoma skin ) , treat untreated , within past five year , regardless whether evidence local recurrence metastasis . 5 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment Investigator , would make subject inappropriate entry study . 6 . Any surgical medical condition possibly affect drug absorption ( e.g . cholecystectomy , gastrectomy , bowel disease , etc . ) , distribution , metabolism excretion . 7 . Previous splenectomy . 8 . A history photosensitivity . 9 . Subject positive follow Antihuman immunodeficiency virus 1 2 antibody ( antiHIV1 antiHIV2 Ab ) ( ELISA ) Hepatitis B surface antigen ( HBsAg ) Antihepatitis B core antibody ( antiHBcAb ) Antihepatitis C antibody ( antiHCV ) 10 . Resting vital sign ( measure 5 minute supine position ) screening , predose ( Part A ) preinoculation ( Part B ) outside follow studyspecific normal range : tympanic body temperature &lt; 38.0 °C 90 &lt; SBP &lt; 140 mmHg 50 &lt; DBP &lt; 90 mmHg 40 &lt; pulse rate &lt; 100 bpm 11 . Symptomatic postural hypotension screening , irrespective decrease blood pressure , asymptomatic postural hypotension define decrease systolic blood pressure ≥20 mmHg 2 minute change supine stand position . 12 . A history clinically significant ECG abnormality , follow ECG abnormality screen , predose ( Part A B ) preinoculation ( Part B ) : PR &gt; 210 m QRS complex &gt; 120 m QTcF &gt; 450 ms Second third degree atrioventricular block Incomplete , complete intermittent bundle branch block Abnormal T wave morphology Left ventricular hypertrophy repolarisation abnormality Right ventricular hypertrophy . 13 . Presence acute infectious disease fever ( i.e . tympanic body temperature ≥38.5 ºC ) within five day prior first dose study medication ( Part A ) inoculation administration ( Part B ) . 14 . Use prescription nonprescription drug , herbal dietary supplement within 14 day 5 halflives ( whichever longer ) prior first dose study medication ( Part A ) inoculation administration ( Part B ) . [ As exception , paracetamol may use dos 1 g/day ( Part A ) 2 g/day ( Part B ) , ibuprofen 1.2 g/day ( Part B ) . Limited use nonprescription medication believe affect subject safety overall result study , may permit casebycase basis follow approval sponsor . ] 15 . Recipient vaccination within 28 day prior first dose study medication ( Part A ) inoculation administration ( Part B ) . 16 . Urine drug screen screening , predose ( Part A ) preinoculation ( Part B ) positive drug list Section 9.2.4 unless explanation acceptable medical Investigator ( e.g . subject state advance consume prescription counter product contain detected drug ) and/or subject negative urine drug screen retest pathology laboratory . 17 . Ingestion poppy seed within 24 hour prior screen blood test . 18 . A positive alcohol breath test screening , predose ( Part A ) preinoculation ( Part B ) . 19 . History regular alcohol consumption exceed weekly intake 21 unit male 14 unit female ( one unit equivalent 810 g ethanol , 285 ml beer lager , one glass [ 125 ml ] wine , 25 ml spirit ) within 6 month screen . 20 . History drug habituation , prior intravenous usage illicit substance . 21 . Participation investigational product study within 12 week five halflives ( whichever longer ) prior first dose study medication . 22 . Intake grapefruit , grapefruit juice grapefruitrelated citrus fruit ( e.g . Seville orange , pomelo ) within 28 day prior first dose study medication . 23 . Excessive consumption beverage contain xanthine base ( e.g . 400 mg caffeine per day , equivalent approximately 4 cup coffee ) . 24 . Pregnant nursing ( lactate ) woman . 25 . Participation research study involve blood sampling ( 450 ml/ unit blood ) , blood donation Australian Red Cross Blood Service ( ARCBS ) blood bank 8 week prior IMP administration ( Part A ) inoculation ( Part B ) . 26 . Blood donation ( exclude plasma donation ) volume , within 1 month prior screen . 27 . Medical requirement intravenous immunoglobulin blood transfusion . 28 . Subject poor peripheral venous access . 29 . Subject unwilling unable comply restriction describe protocol . 30 . Any subject , judgment Investigator , likely noncompliant study , unable cooperate language problem poor mental development . 31 . Any subject Investigator subinvestigator , research assistant , pharmacist , study coordinator , staff thereof , directly involve conducting study . 32 . Recent ( within last three year ) and/or recurrent history autonomic dysfunction ( e.g . recurrent episode fainting , palpitation , etc . ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>malaria , single ascend dose ,</keyword>
</DOC>